Dr. Marty Makary Was Paid $130,357 By Pharma.  Is His “Undue Influence” Affecting the FDA?

Key Takeaways

• Makary received $130,357 from pharma before FDA role
• He pledged no pharma work, yet holds board seats
• Critics warn revolving door fuels FDA corruption risk
• Makary appointed former industry execs to key FDA posts
• Conflicts may undermine public trust in drug approvals

Summary

Dr. Marty Makary, now FDA commissioner, earned $130,357 from pharma firms before his nomination and serves on the board of an ophthalmic drug company despite pledging never to work for big‑pharma. He appointed former industry executive Dr. George Tidmarsh to head CDER, sparking controversy over potential bias. Critics highlight a revolving‑door pattern that may compromise regulatory impartiality. The article argues that undisclosed financial ties could erode public trust in FDA decisions.

Pulse Analysis

Dr. Marty Makary, a high‑profile surgeon turned FDA commissioner, disclosed that he earned $130,357 from Harrow Health and related pharma entities during the two years preceding his nomination. Although he publicly pledged never to work for big‑pharma, he simultaneously serves on the board of an ophthalmic drug company and advises several health‑tech firms. This juxtaposition raises immediate questions about the depth of his financial ties and whether they could subtly shape regulatory priorities, especially in areas where his advisory roles intersect with FDA oversight. Such disclosures also invite scrutiny from congressional oversight committees.

The broader “revolving door” phenomenon—regulators moving to industry and vice‑versa—has long been flagged as a systemic vulnerability. Critics argue that former FDA officials who later accept lucrative consulting contracts may carry industry bias back into policy discussions, while current officials with private sector earnings risk favoring products that benefit their benefactors. Makary’s appointment of Dr. George Tidmarsh, a former biotech CEO, to head CDER exemplifies this trend, and the subsequent controversy surrounding Tidmarsh’s tenure fuels skepticism about impartial drug evaluation. Transparency measures, such as public registries of payments, could mitigate these risks.

If perceived conflicts are not addressed, confidence in the agency’s decisions could erode, influencing everything from investor sentiment to patient willingness to adopt new therapies. Policymakers may respond by tightening conflict‑of‑interest disclosures, imposing cooling‑off periods, or mandating independent review panels for high‑risk approvals. For pharmaceutical companies, clearer rules could level the playing field, reducing the advantage of insiders while preserving legitimate expertise. Ultimately, transparent governance is essential to maintain the FDA’s credibility and to ensure that public health, not private profit, drives regulatory outcomes. Stakeholders across the healthcare ecosystem will watch closely as reforms unfold.